Dna Repair Therapy For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
DNA repair therapy aims to counteract the accumulation of DNA damage that occurs with aging and is accelerated in neurodegenerative diseases. This approach includes enhancing base excision repair, nucleotide excision repair, and other DNA repair pathways to protect neuronal genomes and maintain cellular function. [1]
'''DNA Repair Therapy for Neurodegenerative Diseases''' addresses the accumulating DNA damage that occurs in aging neurons and is accelerated in neurodegenerative conditions. This page covers the role of DNA damage in neurodegeneration, therapeutic strategies to enhance DNA repair, and clinical applications. [2]
{| class="infobox" [3]
|- [4]
! colspan="2" style="background:#e8f4ea;font-size:120%;" | DNA Repair Therapy
|-
| '''Category''' || Therapeutic Intervention
|-
| '''Target Conditions''' || AD, PD, ALS, HD, Ataxias, Stroke
|-
| '''Mechanism''' || Enhance DNA repair pathways
|-
| '''Delivery Routes''' || Oral, IV, Gene therapy
|-
| '''Clinical Stage''' || Preclinical to Phase II
|-
| '''Key Targets''' || PARP, BER, NER, HR
|}
== Overview ==
Neurons are post-mitotic cells that cannot divide, making them unable to replicate their DNA. Over a lifetime, neurons accumulate oxidative DNA damage, single-strand breaks, and double-strand breaks. In neurodegenerative diseases, this damage accumulates faster due to increased oxidative stress, mitochondrial dysfunction, and impaired repair mechanisms.
== DNA Repair Pathways in the Brain ==
=== Base Excision Repair (BER) ===
=== Mitochondrial DNA Repair ###
=== Double-Strand Break Repair ===
== Therapeutic Strategies ==
=== PARP Inhibitors ===
=== DNA Glycosylase Enhancers ===
=== Polynucleotide Kinase Phosphatase (PNKP) Modulators ===
=== Gene Therapy Approaches ===
=== Antioxidant-Dependent Protection ===
== Disease-Specific Applications ==
=== Alzheimer's Disease ===
=== Parkinson's Disease ===
=== Amyotrophic Lateral Sclerosis (ALS) ===
=== Huntington's Disease ===
=== Ataxia-Telangiectasia ===
=== Stroke ===
== Clinical Trial Status ==
{| class="wikitable"
|-
! Agent
! Condition
! Phase
! Status
! Trial ID
|-
| PJ34
| ALS
| Preclinical
| Ongoing
| — |
|---|
| Olaparib |
| PD |
| Phase I |
| Recruiting |
| NCT03980908 |
| - |
| EPI-743 |
| ALS/PD |
| Phase II |
| Completed |
| NCT01962346 |
| - |
| Ribavirin |
| Ataxia |
| Phase II |
| Completed |
| NCT01814469 |
| } |
== Challenges and Limitations ==
== Combination Approaches ==
== Future Directions ===
== See Also ==
== References ==
The study of Dna Repair Therapy For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Jeppesen DK, Bohr VA, Stevnsner T. DNA repair deficiency in neurodegeneration. 2011. ↩︎
Rass U, Ahel I, West SC. Defective DNA repair and neurodegenerative disease. 2007. ↩︎
Hoeijmakers JH. DNA damage, aging, and cancer. 2009. ↩︎
Bedoyan JK, DeGrauw TJ, Bohan TP. DNA repair in neurodegenerative disease. 2012. ↩︎